{
    "root": "5bec0e35-b44e-4712-a29d-021160b52810",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "FAMOTIDINE",
    "value": "20250509",
    "ingredients": [
        {
            "name": "FAMOTIDINE",
            "code": "5QZO15J2Z8"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, UNSPECIFIED",
            "code": "9XZ8H6N6OH"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A",
            "code": "H8AV0SQX4D"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        }
    ],
    "indications": "Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of:\n                  \n                     \n                        •active duodenal ulcer (DU).\n                     \n                        •active gastric ulcer (GU).\n                     \n                        •symptomatic nonerosive gastroesophageal reflux disease (GERD).\n                     \n                        •erosive esophagitis due to GERD, diagnosed by biopsy.\n                  \n                  Famotidine tablets are indicated in adults for the:\n                  \n                     \n                        •treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias).\n                     \n                        •reduction of the risk of duodenal ulcer recurrence.",
    "contraindications": "Indication Recommended Dosage ( 2.1 ) Adult and Pediatric Patients 40 kg and greater Active DU 40 mg once daily; or 20 mg twice daily Active Gastric Ulcer 40 mg once daily GERD 20 mg twice daily Erosive Esophagitis 20 mg twice daily; or 40 mg twice daily Adults Pathological Hypersecretory Conditions 20 mg every 6 hours; adjust to patient needs; maximum 160 mg every 6 hours Risk Reduction of DU Recurrence 20 mg once daily • See full prescribing information for complete dosing information, including dosing in renal impairment, and recommended treatment duration. ( 2.1, 2.2 ) Administration ( 2.3 ): • Take once daily before bedtime or twice daily in the morning and before bedtime with or without food.",
    "warningsAndPrecautions": "Famotidine tablets are supplied as, round, white to off-white Film-coated tablets, debossed with “V” on one side and “16” on the other side.\n                  \n                     \n                         Bottles of 14\tNDC 68788-8518-4\n                     \n                         Bottles of 30\tNDC 68788-8518-3\n                     \n                         Bottles of 60\tNDC 68788-8518-6\n                     \n                         Bottles of 90\tNDC 68788-8518-9\n                  \n                  Storage\n                  Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) (See USP Controlled Room Temperature). Dispense in a USP tight, light-resistant container.",
    "adverseReactions": "Famotidine tablets are contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or other histamine-2 (H2) receptor antagonists."
}